[1] Jones C, Plummer E R. PARP inhibitors and cancer therapy-early results and potential applications [J]. Br J Radiol, 2008, 81(l): S2-S5. [2] Drew Y, Plummer R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications [J]. D...
1.PETRA:First in class,first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients(pts)with BRCA1/2,PALB2 or RAD51C/D mutations. 2.Fauzee,N.J.,J.Pan,and Y.L.Wang,PARP and PAR...
Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360–394 (2020). CAS PubMed PubMed Central Google Scholar Pilié, P. G., Tang, C., Mills, G. B. & Yap, T. A. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat. Rev. Cli...
2. Fauzee,N.J., J. Pan, and Y.L. Wang, PARP and PARG inhibitors--newtherapeutic targets in cancer treatment. Pathol Oncol Res, 2010.16(4): p. 469-78; 3. PDB药物综合数据库。
(3)Bryant,H.E., et al., Specific killing of BRCA2-deficient tumours withinhibitors of poly(ADP-ribose) polymerase. Nature, 2005. 434(7035):p. 913-7. (4)Slade,D., PARP and PARG inhibitors in cancer treatment. Genes Dev, 2020.34(5-6): p. 360-394. ...
Slade D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 2020;34(5–6):360–94. https://doi.org/10.1101/gad.334516.119. Article CAS PubMed PubMed Central Google Scholar Iyer S, Suresh S, Guo D, Daman K, Chen JCJ, Liu P, et al. Precise therapeutic gene correction by a...
PARP1 is overexpressed in a variety of cancers and its expression has been associated with overall prognosis in cancer, especially breast cancer [5]. PARP inhibitors in clinical development mimic the nicotinamide moiety of nicotinamide adenine dinucleotide, and bind to the enzyme's catalytic domain,...
Rouleau, M., Poirier, G.G. (2004). Potential Role of PARP Inhibitors in Cancer Treatment and Cell Death. In: Panasci, L.C., Alaoui-Jamali, M.A. (eds) DNA Repair in Cancer Therapy. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-592...
et al. A potent and selective PARP11 inhibitor suggests coupling between cellular localization and catalytic activity. Cell Chem. Biol. 25, 1547–1553 (2018). Article CAS PubMed Google Scholar Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360–394 (2020). Article...
PARP1 is overexpressed in a variety of cancers and its expression has been associated with overall prognosis in cancer, especially breast cancer [5]. PARP inhibitors in clinical development mimic the nicotinamide moiety of nicotinamide adenine dinucleotide, and bind to the enzyme's catalytic domain,...